Jeffrey Lyle Gray

This inventor holds 23 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Aerpio Therapeutics, Inc., The Procter Gamble Company, Warner Chilcott Company, LLC. Active years: 2001-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey Lyle Gray. Retrieved from https://idiyas.com/inventor/jeffrey-lyle-gray

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 5)

% Patents Active = 52.2

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 4.4

ph-index = 17

Forward Citations = 657(Granted Patents)

Company Filing History:

11 out of 35

Aerpio Therapeutics, Inc.

patents

9 out of 17,692

The Procter Gamble Company

patents

2 out of 39

Warner Chilcott Company, LLC

patents

4. 1 out of 8

Aerpio Pharmaceuticals, Inc.

patents

Years Active: 2001-2019

Loading Chart...

Areas of Expertise:

Protein Tyrosine Phosphatase

Inhibitors

Antimicrobial Quinolones

Compositions

Benzoic Acid Compounds

Human Proteins

Pharmaceutical Applications

Drug Development

Therapeutic Uses

Chemical Processes

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10463650 - Human protein tyrosine phosphatase inhibitors and methods of use (2019-11-05),

2. RE46592 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-30),

3. 9795594 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-24),

4. 9284285 - Human protein tyrosine phosphatase inhibitors and methods of use (2016-03-15),

5. 9126958 - Human protein tyrosine phosphatase inhibitors and methods of use (2015-09-08),

6. 8946232 - Human protein tyrosine phosphatase inhibitors and methods of use (2015-02-03),

7. 8895563 - Human protein tyrosine phosphatase inhibitors and methods of use (2014-11-25),

8. 8846685 - Human protein tyrosine phosphatase inhibitors and methods of use (2014-09-30),

9. 8338615 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-12-25),

10. 8329916 - Human protein tyrosine phosphatase inhibitors and method of use (2012-12-11),

11. 8258311 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-09-04),

12. 8188125 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-05-29),

13. 8106078 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-01-31),

14. 7795444 - Human protein tyrosine phosphatase inhibitors and methods of use (2010-09-14),

15. 7622593 - Human protein tyrosine phosphatase inhibitors and methods of use (2009-11-24),

Title: Innovations and Contributions of Jeffrey Lyle Gray

Introduction

Jeffrey Lyle Gray, based in Loveland, Ohio, is a prominent inventor known for his significant contributions to biotechnology and pharmaceutical research. With a remarkable portfolio of 23 patents, he has made strides in the field of human protein tyrosine phosphatase inhibitors that play crucial roles in regulating angiogenesis.

Latest Patents

Among his latest innovations, Gray has developed compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors. These compounds are pivotal in regulating angiogenesis, which is the process of forming new blood vessels. The patents detail not only the inhibitors but also the compositions and methods for utilizing these inventions to aid in therapeutic applications.

Career Highlights

Gray's career has included significant tenures at reputable companies such as Aerpio Therapeutics, Inc. and The Procter & Gamble Company. His work has centered around utilizing innovative approaches to solve complex biological problems, particularly those associated with vascular diseases.

Collaborations

Throughout his career, Gray has collaborated with notable colleagues, including Kande K D Amarasinghe and Cynthia Monesa Clark. These collaborations have contributed to advancing research and enhancing the effectiveness of his inventions within the scientific community.

Conclusion

Jeffrey Lyle Gray stands out as a visionary inventor in the biotechnology sector. His extensive work with protein inhibitors has the potential to transform therapeutic strategies for treating various diseases related to angiogenesis. Through his inventions, Gray continues to impact the field and inspire future innovations in medicine.

Profile summary based on public USPTO records.